Combination thiopurine-infliximab (IFX) therapy is associated with reduced generation of antidrug antibodies (ADA) compared with IFX monotherapy. Whether past clinical response to thiopurine therapy bears an effect on ADA prevention is unknown.
L oss of response to anti-tumor necrosis factor agents occurs in up to 13% of patients annualy 1 and significantly impacts long-term efficacy of these agents. Antidrug immunogenicity is one of the main causes for loss of response. Several studies demonstrated that infliximab (IFX)-thiopurines cotherapy (combination) reduces antidrug antibody (ADA) The mechanism by which thiopurines exert their effect is still not fully elucidated, suggesting that the ADA-protective effect may differ from the clinical anti-inflammatory effect. However, combination therapy is associated with enhanced immune suppression and increased risks for infection and malignancy. [2] [3] [4] Thus, identifying the subgroups of patients who benefit most from combination therapy is a pertinent issue, which may help avoid combination therapy in patients unlikely to benefit from such intervention. Specifically, it is hitherto unknown whether patients who clinically failed prior thiopurine therapy still benefit from combination therapy with respect to prevention of antidrug immunogenicity, or whether this practice exposes them to unnecessary risks, which are not associated with a clinical benefit. Therefore, we aimed to examine the impact of past thiopurine response on ADA appearance in patients with Crohn's disease cotreated with IFX. A secondary objective was to compare the risk of ADA appearance between the 3 IFX-thiopurine combination subgroups and the monotherapy group.
Methods

Patients
This was a retrospective observational cohort study. Inclusion criteria were patients with Crohn's disease treated by !4 scheduled IFX infusions (0, 2, 6, and 14 weeks) who had a documentation of response/nonresponse to past/ongoing thiopurine treatment (see below), and had serial trough ADA measurements. Patients who had early (before week 14) appearance of ADA, and did not reach Week 14 infusion, were also included in this study. Patients treated with methotrexate-IFX cotherapy, patients treated by episodic IFX therapy, those who did not receive induction therapy, or those who had a long drug holiday (>10 weeks between treatments) were excluded from analysis. Past exposure to adalimumab was permitted. All data were collected from patients' medical records. Patients were classified into 4 groups, IFX monotherapy and 3 combined IFX-thiopurine groups according to classification of past outcome of thiopurine therapy: primary failure, past response, and de novo combination (no thiopurine exposure before IFX initiation). The internal review board of each institution authorized the study.
Past Thiopurine Response Definitions
Primary thiopurine failure was defined as active disease despite more than 3 months of adequate dosing (>1 mg/kg for mercaptopurine and >2 mg/kg for azathioprine if no adverse effects were reported) and good adherence to therapy as documented by the treating physician. Active disease was defined in the study protocol as symptomatic patients who failed to discontinue concurrent steroids, or had to switch/add biologic therapy or another immunomodulator, or needed disease-related surgery. Past response group included patients with secondary thiopurine failure, defined as patients who had disease exacerbation after a good initial response (>6 months steroid independent) to thiopurines. Physicians and patients were contacted if no data were found in the medical record. Patients with no data on thiopurine exposure were excluded from the study.
Antidrug Antibody and Drug Level Assays
ADA and drug levels were performed on trough serum samples at each center laboratory: Tel Aviv Sourasky Medical Center used kits manufactured by Immunodiagnostik systems (Frankfurt, Germany); Leuven University Hospital used a self-developed bridging enzyme-linked immunosorbent assay as previously described. 5 Sheba Medical Center and Rambam Health Care Campus determined ADA level using a self-developed antilambda chain assay, as previously described. 6 Because no significant differences in drug serum levels between different kits were reported in the past, 7 drug level analysis compiled drug concentration data from all centers.
Primary Endpoint and End of Follow-Up
The primary endpoint was ADA appearance during the first treatment year, defined as a positive ADA result according to the positivity cutoff level as defined by each center. Patients were followed and included in the analysis up to the primary endpoint or one of the end of follow up points: last follow-up visit or first change in therapy (shortening IFX intervals, IFX dose escalation, IFX discontinuation, immunomodulator drug added [including oral steroids], or change in thiopurine therapy).
Additional Potential Determinants of Antidrug Antibody Appearance
Collected information included age, gender, ethnicity, smoking status, body mass index, age at diagnosis, disease behavior and anatomic location according to the Montreal classification, extraintestinal manifestations, perianal disease, past surgery, concomitant intravenous (IV) steroid treatment (200 mg IV hydrocortisone), and time from diagnosis to start of IFX.
Clinical Status at the End of Follow-Up
Given the retrospective nature of this study a standard definition of response was not possible. Therefore, response and remission were defined according to the treating physician's comments in the patient's chart. To objectively substantiate the clinical observation, improvement from pretreatment baseline of biomarkers of inflammation was also required. These included serum C-reactive protein, fecal calprotectin, and/or endoscopic activity assessment before and after IFX/thiopurine initiation.
Statistical Analyses
The chi-square test and Fisher exact test were performed to determine significant differences in categorical baseline demographic and clinical variables among the 4 compared treatment groups. Analysis of variance or the nonparametric Kruskal-Wallis tests was used for continuous variables according to data distribution. KaplanMeier analysis was used to compare ADA-free survival among the 4 groups. The differences in survival among the groups were evaluated with log-rank test. Because ADA mostly appears during the first year of therapy 8 and because of the small number of patients in each of the combined treatment groups we limited the survival analysis to 1 year follow-up. To detect a difference of 20% in the 1-year cumulative incidence of ADA with power of 0.8 and a of 0.05 we needed 60 patients in each thiopurine response group. The actual sample size that we reached of 34 and 52 patients allowed detection of such difference with power of 0.6. Cox proportional hazards model was constructed to determine the independent hazard ratio (HR) of 1-year ADA appearance risk by past thiopurine response and between 1-year ADA appearance risk in combination treatments compared with monotherapy, adjusting for other potential determinants of ADA appearance. HR for ADA appearance between the compared groups and 95% CI were calculated. Covariates at the model included demographic and clinical characteristics that were significantly different among the 4 treatment groups (Table 1) . Study center was entered to the multivariate model because of differences (although not statistically significant) in treatment groups and because of the use of different ADA assays in different centers. Statistical significance was defined as a 2-tailed P < .05. All analyses were performed using SPSS version 19(IBM Corp, Armonk, NY).
Results
Study Groups
A total of 494 patients with serial ADA measurements collected between 2008 and 2014 were reviewed. Two hundred and eighty-seven patients were excluded from analysis as shown in Figure 1 . Two hundred and seven patients were included in the final analysis: 93 received IFX monotherapy and 114 received IFX-thiopurines cotherapy (34 were defined as previous primary thiopurines failures, 52 defined as previous primary thiopurines responders, and 28 received de novo combination treatment). The median follow-up duration (as defined by study protocol) across all study groups was 7.4 months (interquartile range, 4.9-17.8). Table 1 presents the baseline characteristics of patients by study group. No significant differences were found between study groups in most demographic and clinical parameters. The age at Crohn's disease diagnosis was older in the de novo group albeit not clinically significant. Time from diagnosis to IFX use was shorter in the de novo combination group compared with other groups. Penetrating disease behavior was significantly less frequent in patients with past thiopurine response. The proportion of patients who received IV steroids before IFX dose was more common in the primary failure group compared with IFX monotherapy and past thiopurine responders groups.
Patients reached end of follow-up (as stated previously) because of the following: ADA appearance in 36.7%, 31.4% stopped/changed IFX regimen, 18.4% reached their last follow-up, 12.6% changed their thiopurine status, and only 1% was lost to follow-up.
Antidrug Antibody Appearance
Kaplan-Meier analysis revealed a significant difference between patients treated by IFX monotherapy and all patients treated with thiopurines regardless to their past response (Figure 2A) . No difference was observed in the 1-year cumulative risk for ADA development between past thiopurine responders (19.3%) and past thiopurine failures (16.1%) (log-rank P ¼ .54). The highest risk for ADA was found in the monotherapy group (46.6%) and was significantly different compared with past thiopurine treatment groups: 19.3% for past responders (P ¼ .007) and 16.1% for past failures (P ¼ .007). A trend for difference between monotherapy and de novo combination group was observed (21.9%), but underpowered for statistical significance (P ¼ .102) ( Figure 2B) . In a multivariate analysis, adjusting for Montreal B classification, age at diagnosis, time to IFX onset, study center, and IV steroid pretreatment, no significant difference in ADA development was observed between past thiopurine failures compared with responders (HR, 0.7; 95% CI, 0.2-2.3; P ¼ .56) ( Table 2 ). The hazards for ADA development were significantly lower in past responders and past failures compared with the monotherapy group (HR, 0.47 [95% CI, 0.22-1.00] and 0.32 [95% CI, 0.11-0.93], respectively), whereas a nonsignificant trend was noted in the de novo combination group (HR, 0.47; 95% CI, 0.19-1.12). Age at diagnosis significantly affected ADA formation. The type of thiopurine in the combination groups did not significantly impact ADA appearance: 24.6% developed ADA on azathioprine and 17.9% developed ADA on mercaptopurine (P ¼ NS).
We next looked at differences in the dynamics of ADA formation among the groups. The cumulative risk of ADA development at 6 months was also significantly higher in the monotherapy group (35.1%) versus past responders (13.9%; P ¼ .014) and past failures (9.6%, P ¼ .012). However, the frequency of ADA formation in the monotherapy and de novo combination group curves diverges only after 5 months of therapy. Cumulative risk of ADA development at 5 months from IFX initiation was (24.7%) in the monotherapy group and (21.9%) in the de novo combination group (P ¼ .728). In the following 7 months up to 1 year, no new ADA events were recorded in the de novo combination group (0%) versus (29.9%) in the monotherapy group (P ¼ .024). Of note, most patients with positive ADA had persistently positive ADA measurements (not transiently detected). Forty patients on IFX monotherapy received IV steroids pretreatment. Interestingly, corticosteroid premedication did not alter ADA appearance in the IFX monotherapy group (41.0% with pretreatment vs 44.2% without; P ¼ .760).
Study center was found to significantly impact ADA positivity (Table 2) : it was significantly more common at Rambam Health Care Campus and Sheba Medical Center as compared with Leuven University Hospital and Tel Aviv Sourasky Medical Center. After adjustment to all model variables study center still had overall significant effect on ADA appearance (P ¼ .028). When monotherapy was compared with all combination groups within each center's cohort, ADA positivity was more common during monotherapy in every center, although this did not reach statistical significance because of the small sample size in each center.
Drug Levels
Significantly lower IFX serum concentrations were observed in ADA-positive compared with ADA-negative patients at the end of follow-up: the median was 0.3 mg/mL (interquartile range, 0.00-1.66) for ADA-positive and 2.33 mg/mL (interquartile range, 0.76-5.67) for ADA-negative (P < .001). This effect occurred in all study groups, regardless of the therapy or treating center. The proportion of patients with IFX drug levels less than 3 mg/mL at the end of follow-up was higher in the monotherapy group compared with all combination groups compiled (70.0% and 60.2%, respectively), but was not significant (P ¼ .146).
Clinical Status at End of Follow-Up
Because of small sample size all thiopurine combination groups were compiled and compared with monotherapy group. As compared with the combination groups, patients in the monotherapy group were more likely to have active disease (21.5% vs 8.8%, respectively), and subsequently less likely to be in remission (40.9% compared with 58.8% of the combination group; P ¼ .009) (Figure 3 ). This trend was consistent after stratifying to ADA-positive patients and ADA-negative patient (although not significant). No significant differences in clinical response were noted between the different combination groups.
Discussion
The findings from our retrospective cohort study suggest that adding a thiopurine to IFX therapy prevents ADA formation independently of the past clinical response to thiopurines. This effect was consistent after adjustment to clinical-and treatment-related factors.
The results support the contention that prevention of ADA formation probably has a clinical impact, because more patients in the combination groups (compiled) were in clinical remission at the end of the study compared with the monotherapy group. However, an additional explanation for the better clinical status of the combination groups compared with monotherapy may be direct pharmacologic effects of thiopurines. This was possibly supported by the observation that the difference remained after stratification to ADA formation, although not significant because of small numbers of patients. Not surprisingly, patients with ADA had lower serum drug levels than those without ADA. A nonstatistically significant trend was observed for a higher proportion of patients with IFX drug levels less than 3 mg/mL in the monotherapy group compared with the combination groups. We had an unusually high proportion (60%-70%) of patients with IFX concentrations <3 mg/ mL at the study endpoint. Likely, this stemmed from a bias introduced by the study's endpoint definition of loss of response or ADA development.
The present results need to be interpreted with caution. Because the study was retrospective it may have been underpowered to detect a possible difference between past responders and past nonresponders to thiopurine. Notwithstanding, the present observations suggest that even if such difference does exist, it is probably of small effect size, especially when projected against the significant difference in ADA formation rate between each of these groups and the monotherapy group.
We observed that ADA formation was similar in the de novo combination group and monotherapy groups during the first 5 months of therapy. However, patients in the monotherapy group continued to form ADA throughout the study follow-up period, whereas no new ADA developed in the de novo combination group thereafter, converging with the other combination groups at 1 year. It seems that the lag time between initiation of thiopurines and their effect on ADA prevention is similar to the 3-to 6-months lag between thiopurine initiation and their effect on clinical response as previously observed. 9 To avoid such lag phenomenon it might be recommended to continue thiopurines when the decision to start IFX is made to prevent early ADA appearance. Vermeire et al 10 reported no difference in cumulative incidence of ADA between patients receiving immunomodulator before IFX or in de novo combination therapy, both groups having significantly lower ADA levels compared with monotherapy. However, most of these patients were treated episodically. Thus, prevention of early ADA might not be clinically relevant.
Our study had some limitations. The first is its retrospective nature of clinical data collection and methodologic limitations associated with this approach. However, because the study was based on real-life cohorts from 4 different centers in 2 countries, the data presented herein have a lower propensity for specific treatment bias. A potential bias related to the exclusion of 287/494 of patients reviewed may limit the relevance of our finding to other patient populations, although exclusion criteria were explicit and led to a homogenic and specific study cohort, relevant to the study's question. Second, patients' adherence and actual 6-thioguanine blood levels of thiopurines metabolites could not be assessed in this study and may impact the results. However, as shown in Table 1 , no difference in reported weight-based thiopurine dose (mg/kg) was found between past thiopurine exposure groups. The planned sample size in the combined treatment groups was not reached and thus a type II mistake should be considered as one of the explanations for detecting no difference. Lastly, ADA assays and ADA positivity rates differed between study's centers, with ADA positivity being more common in the 2 centers using the antilambda assay. To address this difference, adjustment to medical center as a covariate in the multivariate analysis was done (although no significant difference in distribution between study groups was noted between study centers) but was not found to alter the results. To avoid interference of serum ADA by serum IFX we looked at a harder endpoint of ADA positivity and serum IFX <3 mg/mL. The difference in ADA formation between study groups was not changed in univariate analysis, and the same trend was noted in multivariate analysis but was not significant (data not shown). Of note, the overall rate of ADA formation in our study was in the range of that reported in past studies. [10] [11] [12] [13] [14] The validity of ADA positivity is also supported by the consistency of our results with other published studies regarding the correlation between ADA and IFX drug levels and clinical status.
In conclusion, in this "real-life" study we observed that adding a thiopurine to IFX therapy is associated with lower rate of ADA appearance, probably regardless of patient's past clinical thiopurine response. Further studies are needed to increase the understanding of factors governing immunogenicity of IFX in some but not all patients and to elucidate the optimal methods to prevent it.
